About UPTRAVI®

Add UPTRAVI® as Part of Early Comprehensive Treatment for FC II and FC III PAH

campaign_image_2

Guidelines Recommendation

book-icon-ellipse

2015 ESC/ERS GUIDELINES: UPTRAVI® is the only oral prostacyclin pathway therapy to receive the highest class recommendation for sequential combination therapy in FC II and FC III1

2015 ESC/ERS Guidelines recommendations mobile image

Adapted from the Eur Resp J. This drug was approved by the EMA at the time of publication of these guidelines.

  • Class I recommendation definition: evidence and/or general agreement that a given treatment or procedure is
    benefical, useful, effective
  • Level B evidence defination: data derived from a single randomized clinical trial or large nonrandomized success

THE 6TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION: Escalation to triple-combination therapy is recommended when the initial treatment approach with double-combination therapy results in an intermediate risk status2

#1 most-prescribed oral prostacyclin pathway therapy in PAH mobile image

How Uptravi® Works

UPTRAVI® selectively targets the IP receptor—a key target within the prostacyclin pathway4,5

ESTABLISHED PROSTANOID RECEPTORS IN THE HUMAN PULMONARY ARTERY
IP receptor is a key relaxant receptor in the human pulmonary artery mobile image
Clinical significance in humans is unknown.